Tumor control by 8 Gy x4 plus anti-CTLA4 was also eliminated when pre-existing immunity was blocked (p < 0.05) (Fig. 3d), indicating that this treatment regimen is also dependent on pre-existing immunity for tumor control. This evidence concerns the gene CTLA4 and neoplasm.